Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Durvalumab Enhances Survival in SCLC
TOPLINE: Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival was 55.9 months for durvalumab vs 33.4 months for placebo. METHODOLOGY: In the ADRIATIC trial, 730…
English